Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Identify new Gene Involved in the Development of Liver Cancer

20.04.2010
Virginia Commonwealth University researchers have identified a new tumor-promoting gene that may play a key role in the development of liver cancer. Levels of the gene’s expression are significantly higher in more than 90 percent of patients with the disease compared to their healthy counterparts.

Researchers at the Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine hope the findings could lead to an effective therapy to target and inhibit the expression of this gene and result in inhibition of cancer growth.

Hepatocellular carcinoma, HCC, or liver cancer, is the fifth most common cancer and the third leading cause of cancer deaths in the world. Treatment options for HCC include chemotherapy, chemoembolization, ablation and proton-beam therapy. Liver transplantation offers the best chance for a cure in patients with small tumors and significant associated liver disease.

In the study published online the week of April 19 in the Early Edition of the journal Proceedings of the National Academy of Sciences, researchers employing a series of molecular studies identified the new oncogene called LSF, and observed that LSF levels are significantly higher in HCC patients compared to healthy individuals.

Further, the team found that LSF plays an important role in the development and progression of HCC, and that inhibiting LSF can reverse the aggressive properties of human liver cancer cells. They have also identified the molecular mechanism by which LSF promotes the growth of tumors.

“Researchers have been studying the role of LSF for more than 25 years in fields outside of cancer, but our work is the first demonstration that LSF plays an important role in HCC,” said principal investigator Devanand Sarkar, Ph.D., MBBS, assistant professor in the Department of Human and Molecular Genetics in the VCU School of Medicine, and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center and a member of the VCU Institute of Molecular Medicine.

“We show a novel mechanism of HCC development by LSF that provides us with fresh insight into the complex etiology and mechanism of carcinogenesis process. Because LSF is increased in such a high percentage of patients, it could be a potential target for therapeutic intervention,” he said.

According to Sarkar, LSF is a transcription factor, which means it can directly regulate the expression of genes. The team has identified specific genes, such as osteopontin, that are directly induced by LSF.

“Osteopontin is a key player in regulating tumor development and progression and the identification of a master regulator of osteopontin, such as LSF, is a very important discovery,” said Sarkar.

The team is currently testing small molecule inhibitors of LSF as a possible therapy for HCC in animal models.

“Analysis of LSF level in biopsy material may one day be used as a prognostic marker for HCC. Clinicians may be able to design treatment strategies based on the LSF level of a patient. For example, a patient with higher LSF level will respond more to LSF inhibitors. Newer combinatorial strategies can be developed incorporating LSF inhibition in one arm,” he said.

This work was supported in part by grants from the Goldhirsh Foundation, the Dana Foundation, the National Institutes of Health, the Samuel Waxman Cancer Research Foundation, National Institute of Environmental Health and the Liver Tissue Cell Distribution System.

About the VCU Massey Cancer Center
The VCU Massey CancerCenter is one of 65 National Cancer Institute-designated institutions that leads and shapes America’s cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers more clinical trials than any other institution in Virginia, serving patients in Richmond and in four satellite locations. Treating all kinds of cancers, its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and, ultimately, to cure cancer. Visit Massey online at www.massey.vcu.edu or call 1-877-4-MASSEY.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 32,000 students in 211 certificate and degree programs in the arts, sciences and humanities. Sixty-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.

Sathya Achia Abraham | EurekAlert!
Further information:
http://www.vcu.edu

Further reports about: Cancer End User Development HCC LSF VCU cancer research health services liver liver cancer specific gene

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>